This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Topchu I , Karnaukhov N , Mazitova A , Yugai V , Voloshin M , Tikhomirova M , Kit O , Frantsiyants E , Kharin L , Airapetova T , Ratner E , Sabirov A , Abramova Z , Serebriiskii I , Boumber Y , Deneka A
Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)
J Thorac Dis. 2021 Mar;13(3) :1370-1379
PMID: 33841930 PMCID: PMC8024834
AbstractBACKGROUND: Musashi-2 (MSI2) is a member of RNA-binding protein family that regulates mRNA translation of numerous intracellular targets and influences maintenance of stem cell identity. This study assessed MSI2 as a potential clinical biomarker in non-small cell lung cancer (NSCLC). METHODS: The current study included 40 patients with NSCLC, of whom one presented with stage 1, 14 presented with stage II, 15 presented with stage III, and 10 patients had stage IV. All patients received standard of care treatments. All patient samples were obtained before treatment started. We used immunohistochemical (IHC) approach to measure MSI2 protein expression in matching specimens of normal lung versus tumor tissues, and primary versus metastatic tumors, followed by correlative analysis in relation to clinical outcomes. In parallel, clinical correlative analysis of MSI2 mRNA expression was performed in silico using publicly available datasets (TCGA/ICGC and KM plots). RESULTS: MSI2 protein expression in patient samples was significantly elevated in NSCLC primary tumors versus normal lung tissue (P=0.03). MSI2 elevated expression positively correlated with a decreased progression free survival (PFS) (P=0.026) combined for all stages and with overall survival (OS) at stage IV (P=0.013). Elevated MSI2 expression on RNA level was confirmed in primary tumor versus normal tissue samples in TCGA dataset (P<0.0001), and positively correlated with decreased OS (P=0.02). No correlation was observed between MSI2 expression and age, sex, smoking, and treatment type. CONCLUSIONS: Elevated MSI2 expression in primary NSCLC tumors is associated with poor prognosis and can be used as a novel potential prognostic biomarker in NSCLC patients. Future studies in an extended patient cohort are warranted.
Notes2077-6624 Topchu, Iuliia Karnaukhov, Nikolai Mazitova, Alexandra Yugai, Veronika Voloshin, Mark Tikhomirova, Mariya Kit, Oleg Frantsiyants, Elena Kharin, Leonid Airapetova, Tamara Ratner, Ekaterina Sabirov, Alexey Abramova, Zinaida Serebriiskii, Iliya Boumber, Yanis Deneka, Alexander P30 CA006927/CA/NCI NIH HHS/United States P30 CA060553/CA/NCI NIH HHS/United States R01 CA218802/CA/NCI NIH HHS/United States R21 CA223394/CA/NCI NIH HHS/United States Journal Article J Thorac Dis. 2021 Mar;13(3):1370-1379. doi: 10.21037/jtd-20-2787.